2024-12-30 |
2024-12-30 |
V
Vente
|
Tyree James L
Administrateur non-exécutif
|
3 460
-7.0%
2,46
8 512 USD
|
3 460
-7.0%
|
2,46
|
8 512 USD
|
|
2024-12-18 |
2024-12-16 |
VP
Vente planifiée
|
Zak Lourie S.
Chief Financial Officer
Dirigeant
|
2 103
-4.9%
2,34
4 921 USD
|
2 103
-4.9%
|
2,34
|
4 921 USD
|
|
2024-12-18 |
2024-12-16 |
VP
Vente planifiée
|
Smalling Ralph
Head of Regulatory
Dirigeant
|
2 510
-13.3%
2,34
5 873 USD
|
2 510
-13.3%
|
2,34
|
5 873 USD
|
|
2024-12-18 |
2024-12-16 |
V
Vente
|
Cappello Joseph
VP, Pharmaceutical Development
Dirigeant
|
6 300
-30.1%
2,34
14 742 USD
|
6 300
-30.1%
|
2,34
|
14 742 USD
|
|
2024-12-18 |
2024-12-16 |
VP
Vente planifiée
|
Zindrick Thomas
President and CEO
Administrateur exécutif
|
14 315
-27.7%
2,34
33 497 USD
|
14 315
-27.7%
|
2,34
|
33 497 USD
|
|
2024-09-13 |
2024-09-13 |
V
Vente
|
Szalay Aladar
Actionnaire important
|
33 080
-5.2%
2,57
84 946 USD
|
33 080
-5.2%
|
2,57
|
84 946 USD
|
|
2024-09-13 |
2024-09-12 |
V
Vente
|
Szalay Aladar
Actionnaire important
|
31 777
-4.8%
2,73
86 732 USD
|
31 777
-4.8%
|
2,73
|
86 732 USD
|
|
2024-09-12 |
2024-09-11 |
VP
Vente planifiée
|
Tyree James L
Administrateur non-exécutif
|
1 730
-3.5%
2,60
4 499 USD
|
1 730
-3.5%
|
2,60
|
4 499 USD
|
|
2024-09-11 |
2024-09-11 |
V
Vente
|
Szalay Aladar
Actionnaire important
|
31 376
-4.5%
2,62
82 227 USD
|
31 376
-4.5%
|
2,62
|
82 227 USD
|
|
2024-09-11 |
2024-09-10 |
V
Vente
|
Szalay Aladar
Actionnaire important
|
20 384
-2.8%
2,51
51 182 USD
|
20 384
-2.8%
|
2,51
|
51 182 USD
|
|
2024-09-11 |
2024-09-09 |
V
Vente
|
Szalay Aladar
Actionnaire important
|
23 383
-3.2%
2,70
63 200 USD
|
23 383
-3.2%
|
2,70
|
63 200 USD
|
|
2024-09-06 |
2024-09-03 |
V
Vente
|
Szalay Aladar
Actionnaire important
|
42 818
-5.5%
2,09
89 614 USD
|
42 818
-5.5%
|
2,09
|
89 614 USD
|
|
2024-08-30 |
2024-08-30 |
V
Vente
|
Szalay Aladar
Actionnaire important
|
142 589
-15.4%
2,17
309 846 USD
|
142 589
-15.4%
|
2,17
|
309 846 USD
|
|
2024-08-30 |
2024-08-29 |
V
Vente
|
Szalay Aladar
Actionnaire important
|
107 045
-10.4%
1,98
211 960 USD
|
107 045
-10.4%
|
1,98
|
211 960 USD
|
|
2024-08-30 |
2024-08-28 |
V
Vente
|
Szalay Aladar
Actionnaire important
|
15 918
-1.5%
2,05
32 605 USD
|
15 918
-1.5%
|
2,05
|
32 605 USD
|
|
2024-08-27 |
2024-08-27 |
V
Vente
|
Szalay Aladar
Actionnaire important
|
51 630
-4.7%
2,11
108 862 USD
|
51 630
-4.7%
|
2,11
|
108 862 USD
|
|
2024-08-27 |
2024-08-23 |
V
Vente
|
Szalay Aladar
Actionnaire important
|
40 000
-3.5%
2,29
91 416 USD
|
40 000
-3.5%
|
2,29
|
91 416 USD
|
|
2024-07-08 |
2024-06-24 |
V
Vente
|
Yu Yong
VP, Clinical Trial Operations
Dirigeant
|
6 849
-38.7%
2,12
14 520 USD
|
6 849
-38.7%
|
2,12
|
14 520 USD
|
|
2024-07-08 |
2024-06-24 |
V
Vente
|
Jewett Caroline
Head of Quality
Dirigeant
|
4 961
-23.5%
2,12
10 517 USD
|
4 961
-23.5%
|
2,12
|
10 517 USD
|
|
2024-07-08 |
2024-06-24 |
VP
Vente planifiée
|
Ryder Sean
General Counsel
Dirigeant
|
5 496
-22.1%
2,12
11 652 USD
|
5 496
-22.1%
|
2,12
|
11 652 USD
|
|
2024-05-15 |
2024-05-15 |
V
Vente
|
Szalay Aladar
Actionnaire important
|
17 094
-1.5%
3,66
62 624 USD
|
17 094
-1.5%
|
3,66
|
62 624 USD
|
|
2024-05-15 |
2024-05-14 |
V
Vente
|
Szalay Aladar
Actionnaire important
|
15 426
-1.3%
3,58
55 274 USD
|
15 426
-1.3%
|
3,58
|
55 274 USD
|
|
2024-05-15 |
2024-05-13 |
V
Vente
|
Szalay Aladar
Actionnaire important
|
3 446
-0.3%
3,62
12 478 USD
|
3 446
-0.3%
|
3,62
|
12 478 USD
|
|
2024-05-09 |
2024-05-08 |
V
Vente
|
Szalay Aladar
Actionnaire important
|
13 919
-1.2%
3,82
53 189 USD
|
13 919
-1.2%
|
3,82
|
53 189 USD
|
|
2024-05-09 |
2024-05-07 |
V
Vente
|
Szalay Aladar
Actionnaire important
|
6 025
-0.5%
3,67
22 111 USD
|
6 025
-0.5%
|
3,67
|
22 111 USD
|
|
2024-05-01 |
2024-05-01 |
V
Vente
|
Szalay Aladar
Actionnaire important
|
33 061
-2.7%
3,30
109 161 USD
|
33 061
-2.7%
|
3,30
|
109 161 USD
|
|
2024-05-01 |
2024-04-30 |
V
Vente
|
Szalay Aladar
Actionnaire important
|
20 535
-1.6%
3,12
63 981 USD
|
20 535
-1.6%
|
3,12
|
63 981 USD
|
|
2024-05-01 |
2024-04-29 |
V
Vente
|
Szalay Aladar
Actionnaire important
|
6 403
-0.5%
3,25
20 792 USD
|
6 403
-0.5%
|
3,25
|
20 792 USD
|
|
2024-04-24 |
2024-04-24 |
V
Vente
|
Szalay Aladar
Actionnaire important
|
8 064
-0.6%
3,50
28 251 USD
|
8 064
-0.6%
|
3,50
|
28 251 USD
|
|
2024-04-24 |
2024-04-23 |
V
Vente
|
Szalay Aladar
Actionnaire important
|
22 000
-1.7%
3,49
76 800 USD
|
22 000
-1.7%
|
3,49
|
76 800 USD
|
|
2024-04-24 |
2024-04-22 |
V
Vente
|
Szalay Aladar
Actionnaire important
|
14 331
-1.1%
3,53
50 597 USD
|
14 331
-1.1%
|
3,53
|
50 597 USD
|
|
2024-04-18 |
2024-04-17 |
V
Vente
|
Szalay Aladar
Actionnaire important
|
22 737
-1.7%
3,71
84 425 USD
|
22 737
-1.7%
|
3,71
|
84 425 USD
|
|
2024-04-18 |
2024-04-16 |
V
Vente
|
Szalay Aladar
Actionnaire important
|
48 683
-3.5%
3,53
171 802 USD
|
48 683
-3.5%
|
3,53
|
171 802 USD
|
|
2023-12-18 |
2023-12-15 |
V
Vente
|
Yu Yong
VP, Clinical Trial Operations
Dirigeant
|
5 803
-100.0%
14,18
82 265 USD
|
5 803
-100.0%
|
14,18
|
82 265 USD
|
|
2023-12-18 |
2023-12-15 |
V
Vente
|
Yu Yong
VP, Clinical Trial Operations
Dirigeant
|
26 732
-82.2%
12,94
345 915 USD
|
26 732
-82.2%
|
12,94
|
345 915 USD
|
|
2023-12-14 |
2023-12-13 |
V
Vente
|
Thomas John
Administrateur non-exécutif
|
1 927
-0.4%
13,93
26 839 USD
|
1 927
-0.4%
|
13,93
|
26 839 USD
|
|
2023-12-14 |
2023-12-13 |
V
Vente
|
Thomas John
Administrateur non-exécutif
|
7 073
-1.5%
13,23
93 548 USD
|
7 073
-1.5%
|
13,23
|
93 548 USD
|
|
2023-12-14 |
2023-12-13 |
V
Vente
|
Tyree James L
Administrateur non-exécutif
|
3 347
-49.2%
13,73
45 963 USD
|
3 347
-49.2%
|
13,73
|
45 963 USD
|
|
2023-12-14 |
2023-12-13 |
V
Vente
|
Tyree James L
Administrateur non-exécutif
|
5 653
-45.4%
12,91
73 006 USD
|
5 653
-45.4%
|
12,91
|
73 006 USD
|
|
2023-12-08 |
2023-12-07 |
V
Vente
|
Yu Yong
VP, Clinical Trial Operations
Dirigeant
|
36 800
-53.1%
11,85
435 995 USD
|
36 800
-53.1%
|
11,85
|
435 995 USD
|
|
2023-11-22 |
2023-11-21 |
V
Vente
|
Yu Yong
VP, Clinical Trial Operations
Dirigeant
|
18 665
-21.2%
10,26
191 555 USD
|
18 665
-21.2%
|
10,26
|
191 555 USD
|
|
2023-11-21 |
2023-11-20 |
V
Vente
|
Yu Yong
VP, Clinical Trial Operations
Dirigeant
|
14 594
-14.2%
11,26
164 261 USD
|
14 594
-14.2%
|
11,26
|
164 261 USD
|
|
2023-11-21 |
2023-11-17 |
V
Vente
|
Yu Yong
VP, Clinical Trial Operations
Dirigeant
|
3 541
-3.3%
13,04
46 170 USD
|
3 541
-3.3%
|
13,04
|
46 170 USD
|
|
2023-10-26 |
2023-10-25 |
V
Vente
|
Szalay Aladar
Actionnaire important
|
5 704
-0.4%
19,40
110 638 USD
|
5 704
-0.4%
|
19,40
|
110 638 USD
|
|
2023-10-25 |
2023-10-24 |
VP
Vente planifiée
|
Yu Yong
VP, Clinical Trial Operations
Dirigeant
|
5 200
-4.7%
19,11
99 351 USD
|
5 200
-4.7%
|
19,11
|
99 351 USD
|
|
2023-10-25 |
2023-10-23 |
V
Vente
|
Szalay Aladar
Actionnaire important
|
49 987
-3.5%
19,97
998 365 USD
|
49 987
-3.5%
|
19,97
|
998 365 USD
|
|
2023-10-16 |
2023-10-16 |
VP
Vente planifiée
|
Thomas John
Administrateur non-exécutif
|
881
-0.2%
21,30
18 769 USD
|
881
-0.2%
|
21,30
|
18 769 USD
|
|
2023-10-16 |
2023-10-16 |
VP
Vente planifiée
|
Thomas John
Administrateur non-exécutif
|
2 452
-0.5%
20,50
50 269 USD
|
2 452
-0.5%
|
20,50
|
50 269 USD
|
|
2023-10-11 |
2023-10-10 |
VP
Vente planifiée
|
Yu Yong
VP, Clinical Trial Operations
Dirigeant
|
400
-0.4%
22,91
9 162 USD
|
400
-0.4%
|
22,91
|
9 162 USD
|
|
2023-10-11 |
2023-10-10 |
VP
Vente planifiée
|
Yu Yong
VP, Clinical Trial Operations
Dirigeant
|
4 800
-4.3%
21,94
105 300 USD
|
4 800
-4.3%
|
21,94
|
105 300 USD
|
|
2023-10-10 |
2023-10-05 |
V
Vente
|
Szalay Aladar
Actionnaire important
|
985
-0.1%
25,47
25 090 USD
|
985
-0.1%
|
25,47
|
25 090 USD
|
|
2023-10-10 |
2023-10-05 |
V
Vente
|
Szalay Aladar
Actionnaire important
|
13 266
-0.9%
24,89
330 139 USD
|
13 266
-0.9%
|
24,89
|
330 139 USD
|
|
2023-10-04 |
2023-10-03 |
V
Vente
|
Szalay Aladar
Actionnaire important
|
75 690
-5.0%
25,49
1 929 225 USD
|
75 690
-5.0%
|
25,49
|
1 929 225 USD
|
|
2023-09-29 |
2023-09-28 |
V
Vente
|
Szalay Aladar
Actionnaire important
|
2 289
-0.2%
24,12
55 211 USD
|
2 289
-0.2%
|
24,12
|
55 211 USD
|
|
2023-09-29 |
2023-09-27 |
V
Vente
|
Szalay Aladar
Actionnaire important
|
11 257
-0.7%
24,47
275 459 USD
|
11 257
-0.7%
|
24,47
|
275 459 USD
|
|
2023-09-27 |
2023-09-26 |
VP
Vente planifiée
|
Yu Yong
VP, Clinical Trial Operations
Dirigeant
|
2 203
-2.0%
24,46
53 890 USD
|
2 203
-2.0%
|
24,46
|
53 890 USD
|
|
2023-09-27 |
2023-09-26 |
VP
Vente planifiée
|
Yu Yong
VP, Clinical Trial Operations
Dirigeant
|
1 114
-1.0%
23,51
26 195 USD
|
1 114
-1.0%
|
23,51
|
26 195 USD
|
|
2023-09-27 |
2023-09-26 |
VP
Vente planifiée
|
Yu Yong
VP, Clinical Trial Operations
Dirigeant
|
1 883
-1.7%
22,54
42 442 USD
|
1 883
-1.7%
|
22,54
|
42 442 USD
|
|
2023-09-27 |
2023-09-26 |
V
Vente
|
Szalay Aladar
Actionnaire important
|
9 600
-0.6%
24,51
235 296 USD
|
9 600
-0.6%
|
24,51
|
235 296 USD
|
|
2023-09-27 |
2023-09-26 |
V
Vente
|
Szalay Aladar
Actionnaire important
|
12 740
-0.8%
24,03
306 142 USD
|
12 740
-0.8%
|
24,03
|
306 142 USD
|
|
2023-09-27 |
2023-09-26 |
V
Vente
|
Szalay Aladar
Actionnaire important
|
7 465
-0.5%
22,47
167 739 USD
|
7 465
-0.5%
|
22,47
|
167 739 USD
|
|
2023-09-27 |
2023-09-25 |
V
Vente
|
Szalay Aladar
Actionnaire important
|
1 100
-0.1%
27,81
30 591 USD
|
1 100
-0.1%
|
27,81
|
30 591 USD
|
|
2023-09-27 |
2023-09-25 |
V
Vente
|
Szalay Aladar
Actionnaire important
|
1 900
-0.1%
26,60
50 540 USD
|
1 900
-0.1%
|
26,60
|
50 540 USD
|
|
2023-09-27 |
2023-09-25 |
V
Vente
|
Szalay Aladar
Actionnaire important
|
5 511
-0.4%
25,75
141 908 USD
|
5 511
-0.4%
|
25,75
|
141 908 USD
|
|
2023-09-27 |
2023-09-25 |
V
Vente
|
Szalay Aladar
Actionnaire important
|
3 947
-0.3%
24,82
97 965 USD
|
3 947
-0.3%
|
24,82
|
97 965 USD
|
|
2023-09-25 |
2023-09-22 |
V
Vente
|
Szalay Aladar
Actionnaire important
|
4 621
-0.3%
27,76
128 270 USD
|
4 621
-0.3%
|
27,76
|
128 270 USD
|
|
2023-09-25 |
2023-09-22 |
V
Vente
|
Szalay Aladar
Actionnaire important
|
4 421
-0.3%
26,88
118 853 USD
|
4 421
-0.3%
|
26,88
|
118 853 USD
|
|
2023-09-25 |
2023-09-21 |
V
Vente
|
Szalay Aladar
Actionnaire important
|
4 678
-0.3%
28,82
134 815 USD
|
4 678
-0.3%
|
28,82
|
134 815 USD
|
|
2023-09-25 |
2023-09-21 |
V
Vente
|
Szalay Aladar
Actionnaire important
|
2 871
-0.2%
27,89
80 063 USD
|
2 871
-0.2%
|
27,89
|
80 063 USD
|
|
2023-09-21 |
2023-09-20 |
VP
Vente planifiée
|
Yu Yong
VP, Clinical Trial Operations
Dirigeant
|
6 000
-5.4%
27,96
167 786 USD
|
6 000
-5.4%
|
27,96
|
167 786 USD
|
|
2023-09-21 |
2023-09-20 |
VP
Vente planifiée
|
Ryder Sean
General Counsel
Dirigeant
|
10 000
-94.6%
30,00
300 000 USD
|
10 000
-94.6%
|
30,00
|
300 000 USD
|
|
2023-09-20 |
2023-09-19 |
V
Vente
|
Szalay Aladar
Actionnaire important
|
8 247
-100.0%
27,16
223 979 USD
|
8 247
-100.0%
|
27,16
|
223 979 USD
|
|
2023-09-20 |
2023-09-19 |
V
Vente
|
Szalay Aladar
Actionnaire important
|
23 920
-74.4%
26,21
626 962 USD
|
23 920
-74.4%
|
26,21
|
626 962 USD
|
|
2023-09-20 |
2023-09-18 |
V
Vente
|
Szalay Aladar
Actionnaire important
|
2 927
-36.9%
24,17
70 754 USD
|
2 927
-36.9%
|
24,17
|
70 754 USD
|
|
2023-09-20 |
2023-09-18 |
V
Vente
|
Szalay Aladar
Actionnaire important
|
27 365
-77.5%
23,20
634 895 USD
|
27 365
-77.5%
|
23,20
|
634 895 USD
|
|